BioSight
About
BioSight is a private, clinical-stage biotechnology company focused on developing innovative therapeutics for hematological malignancies and disorders. Their lead product, BST-236 (aspacytarabine), is a proprietary anti-metabolite designed to address unmet medical needs by enabling high-dose chemotherapy.
Key facts
At-a-glance profile data
- Website
- biosight-pharma.com
- Headquarters
- Tel Aviv, Israel
- Founded
- 1999
- Employees
- 3
- Total funding
- $2M
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 30 Jul 2008 | Undisclosed round | $2M | - |
Tech stack
Detected on biosight-pharma.com, last scanned 2 Sept 2026. Run your own scan
- CMS / Builders
- Wix
- Email provider
- Microsoft 365
Add first review
Frequently asked
How much funding has BioSight raised?
BioSight has raised a total of $2M in funding.
How many employees does BioSight have?
BioSight has approximately 3 people on record.